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Introduction: Plasma neutrophil gelatinase-associated lipocalin (NGAL) is reportedly useful for post-cardiac surgery
acute kidney injury (AKI). Although chronic kidney disease (CKD) is a strong risk factor for AKI development, no
clinical evaluation of plasma NGAL has specifically examined AKI occurring in patients with CKD. This study
evaluated plasma NGAL in AKI superimposed on CKD after cardiac surgery.
Methods: This study prospectively evaluated 146 adult patients with scheduled cardiac surgery at 2 general
hospitals. Plasma NGAL was measured before surgery, at ICU arrival after surgery (0 hours), and 2, 4, 12, 24, 36,
and 60 hours after ICU arrival.
Results: Based on the Kidney Disease Improving Global Outcomes (KDIGO) CKD guideline, 72 (49.3%) were
diagnosed as having CKD. Of 146 patients, 53 (36.3%) developed AKI after surgery. Multiple logistic regression
analysis revealed that preoperative plasma NGAL, estimated glomerular filtration rate (eGFR), and operation time are
significantly associated with AKI occurrence after surgery. Plasma NGAL in AKI measured after surgery was
significantly higher than in non-AKI irrespective of CKD complication. However, transient decrease of plasma NGAL
at 0 to 4 hours was observed especially in AKI superimposed on CKD. Plasma NGAL peaked earlier than serum
creatinine and at the same time in mild AKI and AKI superimposed on CKD with increased preoperative plasma
NGAL (>300 ng/ml). Although AKI superimposed on CKD showed the highest plasma NGAL levels after surgery,
plasma NGAL alone was insufficient to discriminate de novo AKI from CKD without AKI after surgery. Receiver
operating characteristics analysis revealed different cutoff values of AKI for CKD and non-CKD patients.
Conclusions: Results show the distinct features of plasma NGAL in AKI superimposed on CKD after cardiac surgery:
1) increased preoperative plasma NGAL is an independent risk factor for post-cardiac surgery AKI; 2) plasma NGAL
showed an earlier peak than serum creatinine did, indicating that plasma NGAL can predict the recovery of AKI
earlier; 3) different cutoff values of post-operative plasma NGAL are necessary to detect AKI superimposed on CKD
distinctly from de novo AKI. Further investigation is necessary to confirm these findings because this study
examined a small number of patients.* Correspondence: kdoi-tky@umin.ac.jp
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Acute kidney injury (AKI) is a severe complication
affecting patients who undergo cardiac surgery. Report-
edly, even slight serum creatinine changes during the
postoperative period increased mortality in a large
cardiac surgery cohort [1]. Nevertheless, the limitations
of serum creatinine for the early detection and accurate
estimation of renal injury in AKI are well known [2].
Therefore, new AKI biomarkers, such as neutrophil
gelatinase-associated lipocalin (NGAL), kidney injury
molecule-1 (KIM-1), and L-type fatty acid-binding
protein (L-FABP), have been studied intensively in
recent years [3-6]. These putatively more sensitive
and more accurate biomarkers are also expected to
facilitate early intervention before the increase of serum
creatinine.
New AKI biomarkers are regarded as having ques-
tionable generalizability and reliability in heterogeneous
populations before clinical use. During the first clinical
evaluations, new AKI biomarkers were examined mostly
in pediatric post-cardiac surgery patients, who have fewer
comorbid diseases and who show more readily apparent
onset of renal insult. In such studies, these new bio-
markers showed excellent performance for AKI prediction
and detection [7,8]. Several studies have excluded patients
with pre-existing renal dysfunction [7-9]. Recently, new
AKI biomarkers have shown less impressive performance
when tested with more-heterogeneous populations [10].
For adult post-cardiac surgery patients including chronic
kidney disease (CKD), urinary NGAL showed a low area
under the curve of the receiver operating characteristic
curve (AUC (area under the curve)-ROC) of 0.6 to 0.7
[11,12]. Results of several clinical studies addressing base-
line renal dysfunction have shown strong effects on the
performance of new AKI biomarkers [13,14].
Plasma NGAL, a new AKI biomarker, has demon-
strated its clinical utility in studies of both pediatric and
adult patients of post-cardiac surgery [12,15-19]. How-
ever, as described above, the performance of plasma
NGAL for AKI diagnosis was also less impressive in
adult post-cardiac surgery patients. Haase-Fielitz and
colleagues reported that the performance of serum
NGAL was not changed after excluding 27 CKD patients
from an adult post-cardiac surgery cohort of 100 pa-
tients [16]. However, it remains unclear whether serum
NGAL predicted AKI superimposed on CKD in their
study. The blood NGAL level is known to be increased
in CKD patients under stable conditions [20-22]. There-
fore, different cutoff values will be necessary to detect
AKI superimposed on CKD distinctly from de novo AKI.
This study was undertaken to evaluate plasma NGAL
as an AKI biomarker with adult post-cardiac surgery
patients with or without preoperative complications
by CKD.Materials and methods
Patient population
A total of 146 adult patients undergoing scheduled car-
diac surgery at Tokyo University Hospital (Tokyo, Japan)
and at Itabashi Chuo Medical Center (Tokyo, Japan)
were studied prospectively. Patients with end-stage renal
disease or a renal transplant were excluded. The study
protocol, which adhered to the principles of the Declar-
ation of Helsinki, was approved by the Institutional Review
Board of each hospital (The University of Tokyo Insti-
tutional Review Board and the Ethics Committee of the
Itabashi Chuo Medical Center). Informed consent was
obtained from each participant. For each patient, eight
blood samples were obtained for serum creatinine mea-
surement, which corresponded to pre-surgery, 0 h (ICU
arrival), and 2, 4, 12, 24, 36 and 60 h after ICU arrival.
The presence of AKI was defined by the AKIN (Acute
Kidney Injury Network) criteria (an absolute increase in
serum creatinine of greater than or equal to 0.3 mg/dl or
a percentage increase in serum creatinine of greater than
or equal to 50% from the baseline (before surgery)). The
AKI severity was also categorized according to the AKIN
criteria [23]. Pre-existing chronic kidney disease (CKD)
was determined as estimated GFR (eGFR) <60 ml/minute
per 1.73 m2 or positive kidney damage markers, such
as proteinuria (urinary protein of more than 30 mg/g
creatinine or dipstick 1+ or more), urine sediment
abnormalities and structural abnormalities detected by
imaging, or both, according to the KDIGO CKD
guideline [24]. These abnormalities of kidney struc-
ture or function were present for more than three
months. GFR was estimated with the MDRD equation
with a known baseline creatinine value [25]. Two board-
certified nephrologists (KD and DK) independently
reviewed all medical records and confirmed the determin-
ation of CKD.Plasma NGAL measurement
Plasma NGAL was determined at the same time
points of serum creatinine described above (pre-sur-
gery, 0, 2, 4, 12, 24, 36 and 60 h after ICU arrival)
using an NGAL test (Triage; Alere Medical Inc., San
Diego, CA, USA). The test is a point-of-care, fluores-
cence-based immunoassay designed for rapid quantitative
measurement of NGAL in EDTA-anticoagulated whole
blood. Moreover, the extended-range sandwich test was
used for this study [26]. This assay was developed for the
larger quantifiable range of NGAL compared with the
existing competitive assay. The antibodies used in the
sandwich immunoassay were selected to target only
the free form of NGAL, not NGAL in the homodi-
meric form or heterodimeric complexes with matrix
metallopeptidase 9.
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body weight gain
Adjustment of serum creatinine and plasma NGAL was
conducted as described previously [27,28]. Adjusted values
were calculated as follows: adjusted serum creatinine/plasma
NGAL= serum creatinine/plasma NGAL× (1+ (postopera-
tive body weight gain/0.6 × preoperative body weight)).
Statistical analyses
Data were expressed as median (interquartile). Continu-
ous variables were compared using t-tests or Wilcoxon
rank-sum tests when the normality assumption does not
hold. The Tukey–Kramer or Steel-Dwass test were used
for multiple comparison. Categorical variables were com-
pared using the Pearson χ2 or Fisher’s exact test. The per-
formance of urinary biomarkers was determined using
receiver operating characteristic (ROC) curve analysis.
Optimal cutoff values were determined using the Youden
index (sensitivity + specificity − 1). This index is a com-
mon summary measure of the ROC curve, representing
the maximum potential effectiveness of a marker [29].
Cutoff values that provide 95% sensitivity or 95% specifi-
city were also calculated. A meta-analysis reported the
AUC-ROC value of NGAL for AKI after cardiac surgery
was 0.78 (95% confidence interval 0.67 to 0.87) [30]. We
estimated that a sample size of 129 patients would be ne-
cessary to detect a significant difference in AUC-ROC of
0.65 vs. 0.50 (null hypothesis) with the ratio of sample size
in negative/positive 2.0 at 80% power and at a significance
level of 0.05. Wilcoxon signed-rank test was used to com-
pare the postoperative values of serum creatinine and
plasma NGAL with those measured before surgery. These
calculations were performed using software (JMP ver. 9.0;
SAS Institute Inc., Cary, NC, USA and MedCalc Version
12.7.1.0; MedCalc Software, Ostend, Belgium). A conven-
tional criterion of an alpha level of 0.05 was used to deter-
mine statistical significance.
Results
Patient characteristics and preoperative plasma NGAL
This study prospectively analyzed 146 adult patients
who had scheduled cardiac surgery at two general hospi-
tals. Of those, 68 patients (47.6%) were diagnosed as
having CKD defined by the KDIGO guideline [24]. AKI
was diagnosed using the serum creatinine criteria of
AKIN (that is, a minimum of 0.3 mg/dl or 50% increase
in serum creatinine from the baseline measured before
surgery). Of 146 adult post-cardiac surgery patients, AKI
was diagnosed in 53 (36.3%) within three days after sur-
gery (AKIN stage 1, n = 39; stage 2, n = 5; stage 3, n = 9).
Among 53 AKI patients, 24 patients were diagnosed as
having AKI by a minimum of 0.3 mg/dl increase in serum
creatinine. These patients mostly showed mild AKI (AKIN
stage 1, n = 22), although two patients eventually requiredrenal replacement therapy (stage 3, n = 2). Table 1 and
Figure 1 present the prevalence of AKI and CKD, baseline
clinical data, surgical procedures and outcomes of the
enrolled patients in this study.
Serum creatinine and plasma NGAL before surgery in
the AKI group was significantly higher than in the non-
AKI group (1.00 (0.80 to 1.52) mg/dl vs. 0.80 (0.67 to
1.06) mg/dl, P = 0.0004). AKI was observed with greater
relative frequency in the CKD patients than in non-CKD
patients (33 of 68 CKD patients (48.5%) vs. 20 of 78 non-
CKD (25.6%), odds ratio 2.73, 95% CI 1.36 to 5.48). A
significant correlation was found between estimated GFR
and plasma NGAL measured before surgery (R2 = 0.254,
P <0.0001). Although no difference was found in the
frequency of cardiopulmonary bypass (CPB) between the
AKI group and the non-AKI group, the operation time
and CPB time in the AKI group were significantly longer
than in the non-AKI group. The length of ICU stay in the
AKI group was significantly longer. Moreover, renal
replacement therapy was necessary only for AKI patients.
A multiple logistic regression analysis incorporating
parameters with a univariate P-value <0.05 (age, eGFR,
operation time and plasma NGAL before surgery) revealed
that plasma NGAL before surgery was independently
associated with post-surgery AKI occurrence (Table 2).
Postoperative plasma NGAL for detection of AKI, and
prediction of recovery and dialysis requirement
Plasma NGAL was measured before surgery, and at 0, 2,
4, 12, 24 and 36 h after ICU arrival. Plasma NGAL levels
in the AKI group were significantly higher than in the
non-AKI group at all time points. At 12 h and thereafter,
plasma NGAL levels in the non-AKI, mild AKI (AKIN
stage 1), and severe AKI (AKIN stage 2 + 3) groups were
significantly different from each other, indicating that
plasma NGAL can reflect the AKI severity (Figure 2).
Nine of 53 AKI patients required dialysis 12 h after sur-
gery or thereafter. These patients showed significantly
higher plasma NGAL levels before and at 0 and 4 h after
the surgery than non-dialysis requiring AKI patients
showed (Table 3).
Evaluation of plasma NGAL for predicting AKI recov-
ery was conducted in the mild AKI group (n = 39), in
which no patient either died or required dialysis. Plasma
NGAL showed its highest values earlier than serum cre-
atinine did (Figure 3A). The temporal difference between
the peaks of plasma NGAL and serum creatinine was −8
(−24 to 0) h (Figure 3B).
Differences between de novo AKI and AKI superimposed
on CKD
The patients were divided into four groups to clarify the
impact of baseline renal dysfunction as follows: CKD(−)
AKI(−) (n = 54), CKD(−)AKI(+) (n = 20), CKD(+)AKI(−)
Table 1 Patient characteristics and clinical outcomes
Non-CKD, Non-AKI Non-CKD, AKI CKD, Non-AKI CKD, AKI P-value
(n = 58) (n = 20) (n = 35) (n = 33)
Age (y.o.) 67.5 (57.8 to 74.0) 64.5 (53.3 to 73.0) 74.0 (69.0 to 79.0) 69.0 (65.5 to 76.0) 0.0005
Male, n (%) 36 (62.1%) 16 (80.0%) 23 (65.7%) 17 (51.5%) 0.2
Diabetes, n (%) 24 (41.4%) 8 (40.0%) 15 (42.9%) 12 (36.4%) 0.95
Hypertension, n (%) 34 (58.6%) 15 (75.0%) 24 (68.6%) 22 (66.7%) 0.54
Preoperative
Serum Cre (mg/dl) 0.75 (0.61 to 0.83) 0.76 (0.67 to 0.89) 1.13 (1.01 to 1.38) 1.39 (1.01 to 1.96) <0.0001
eGFR (ml/min/1.73 m2) 75.0 (67.2 to 82.1) 71.8 (64.1 to 83.6) 48.5 (35.3 to 53.4) 36.7 (26.1 to 53.0) <0.0001
Plasma NGAL (ng/ml) 61.0 (42.2 to 2.4) 75.5 (61.0 to 121.0) 120.0 (66.7 to 224.0) 209.0 (106.5 to 492.0) <0.0001
Operation
Operation time (minutes) 296 (259 to 358) 330 (280 to 478) 304 (257 to 362) 355 (289 to 420) 0.064
OPCAB, n (%) 11 (19.0%) 5 (25.0%) 10 (28.6%) 6 (18.2%) 0.67
CPB, n (%) 47 (81.0%) 15 (75.0%) 25 (71.4%) 27 (81.8) 0.67
CPB time (minutes) 151 (119 to 204) 168 (132 to 286) 149 (115 to 195) 170 (110 to 228) 0.4
Valve surgery, n (%) 17 (29.3%) 7 (35.0%) 15 (42.9%) 12 (36.4%) 0.62
CABG surgery, n (%) 7 (12.1%) 1 (5.0%) 1 (2.9%) 5 (15.2%) 0.27
Valve + CABG, n (%) 7 (12.1%) 4 (20.0%) 5 (14.3%) 5 (15.2%) 0.86
Aortic graft replacement, n (%) 12 (20.7%) 3 (15.0%) 2 (5.7%) 1 (3.0%) 0.05
Other, n (%) 4 (6.9%) 0 (0.0%) 2 (5.7%) 4 (12.1%) 0.48
Postoperative
Body weight gain (kg) 1.95 (0.77 to 3.30) 2.96 (1.33 to 4.73) 2.04 (1.07 to 3.93) 2.45 (0.64 to 3.88) 0.66
Need for RRT, n (%) 0 (0.0%) 2 (10.0%) 0 (0.0%) 7 (21.2%) 0.0001
ICU stay (day) 3 (2 to 4) 4 (2 to 10) 3 (2 to 4) 4 (2 to 10) 0.0077
CABG, coronary artery bypass grafting; CKD, chronic kidney disease; CPB, cardiopulmonary bypass; OPCAB, off-pump coronary artery bypass grafting; RRT, renal
replacement therapy.
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levels before surgery were significantly higher in the
CKD(−)AKI(+) group than in the CKD(−)AKI(−) group,
and were also higher in the CKD(+)AKI(+) group than
in the CKD(+)AKI(−) group (Table 1 and Figure 4).
Plasma NGAL values measured before surgery in the
CKD(+)AKI(+) group were the highest among these four
groups. However, for eGFR no significant difference was
found between the CKD(+)AKI(+) group and the CKD(+)
AKI(−) group (37.5 ± 14.2 vs. 45.8 ± 10.2 ml/minute per
1.73 m2, P = 0.0716) or between the CKD(−)AKI(+) group
and the CKD(−)AKI(−) group (75.0 ± 13.8 vs. 80.2 ±
16.7 ml/minute per 1.73 m2, P = 0.5097). This result is
consistent with the results of multiple logistic analyses
that both eGFR and plasma NGAL measured before sur-
gery were independently associated with postoperative
AKI occurrence (Table 2).
After surgery, AKI patients with or without CKD com-
plication showed significantly higher plasma NGAL
values than non-AKI patients did. However, the CKD(−)
AKI(+) and the CKD(+)AKI(−) group showed similar
plasma NGAL values for all perioperative sampling points(Figure 4). Results of ROC analysis are presented in Table 4
and Additional file 1: Figure S1. Plasma NGAL showed
fair performance for AKI diagnosis, with AUC-ROC
values above 0.70. It is noteworthy that the cutoff values
of AKI prediction in CKD were higher than those of non-
CKD at all time-points.
Transient decrease of plasma NGAL in AKI superimposed
on CKD
Increased preoperative plasma NGAL in the CKD(+)
AKI(+) group was followed by a transient drop at 0
to 4 h after the surgery (Figure 4). However, the pa-
tients of CKD(+) AKI(+) whose pre-operative plasma
NGAL had already increased before the surgery
(>300 ng/ml) showed further elevation of plasma NGAL
12 h after the surgery and thereafter (Additional file 2:
Figure S2B). In these patients, the highest value of postop-
erative plasma NGAL was observed earlier than serum
creatinine (Additional file 2: Figure S2C, D) as observed in
mild AKI patients (Figure 3). Intraoperative fluid admi-
nistration can cause dilution of blood concentrations of



















•ESRD N = 10
•Renal transplant N = 0
Figure 1 Study flow diagram. Acute kidney injury (AKI) and chronic
kidney disease (CKD) were defined using the AKIN and KDIGO CKD
guideline criteria.
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plasma NGAL by adjustment with body weight gain after
surgery (Additional file 3: Figure S3). Even after adjust-
ment for fluid accumulation, a transient drop of plasma
NGAL at 0 h was observed in the CKD(+)AKI(+) and the
CKD(−)AKI(+) groups.
Discussion
This study evaluated detection of AKI superimposed on
CKD by plasma NGAL measurement in adult post-
cardiac surgery patients. Reports of two large clinical
observational studies described that CKD was found in
approximately 30% of AKI patients in the ICU [31,32].
Nash and colleagues reported that patients with under-
lying CKD were approximately three times more likely




Operation time (minutes) 0.004 (0.001 t
Plasma NGAL before surgery (ng/ml) 0.003 (0.001 t
AKI, acute kidney injury; eGFR, estimated glomerular filtration rate; NGAL, neutrophfunction [33]. Results of this study also clarified that
CKD was associated significantly with AKI occurrence
after cardiac surgery. Hsu and colleagues analyzed a
large community-based cohort of patients with CKD
and reported that AKI superimposed on CKD is a strong
indicator of risk for death or end-stage renal disease
(ESRD) [34]. Therefore, an AKI biomarker that can de-
tect both de novo AKI and AKI superimposed on CKD
is expected to be useful in a clinical setting.
In this study, elevation of plasma NGAL was found to
be an independent risk factor for AKI occurrence after
surgery in addition to preoperative eGFR (Table 2). This
finding suggests that measurement of plasma NGAL in
CKD before surgery will enable identification of high-
risk populations of AKI superimposed on CKD, a strong
predictor of death or ESRD. It is noteworthy that nearly
50% of patients in the present cohort were complicated
with CKD before surgery, whereas previous clinical eva-
luation studies of plasma NGAL on adult post-cardiac
surgery AKI excluded CKD patients or did not analyze the
impact of pre-existing CKD on the performance of plasma
NGAL [12,16,17].
Not only early detection of AKI but early prediction of
recovery is an important factor for the AKI biomarker
because serum creatinine cannot respond quickly to
renal recovery in AKI. In this study, plasma NGAL
started to decrease earlier than serum creatinine did
(Figures 3 and S2). In addition to increased mortality,
mild AKI defined as small serum creatinine elevation
(>0.3 mg/dl or a 50%) will cause delayed ICU discharge
and a subsequently longer stay in the ICU. A biomarker
that can predict the recovery of AKI earlier than serum
creatinine is expected to be helpful in determining ICU
discharge.
Reportedly, blood NGAL levels are inversely and
closely related to eGFR in stable CKD patients [20-22].
Results of the present study also show a significant,
negative correlation between eGFR and plasma NGAL
measured before surgery. These data suggest that de
novo AKI and AKI superimposed on CKD have different
cutoff values. When we classified the patients into four
groups using AKI and pre-existing CKD, the CKD(−)
AKI(+) group and the CKD(+)AKI(−) group showed
similar plasma NGAL levels at all perioperative samplingoefficient (95% confidence interval) P-value
5 to 0.015) 0.22
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Figure 2 Serum creatinine and plasma NGAL values grouped by AKI severity. Values of serum creatinine (A) and plasma neutrophil
gelatinase-associated lipocalin (NGAL) (B) for acute kidney injury (AKI) severity categories (No AKI (n = 89), Mild AKI (n = 39), Severe AKI (n = 14)).
#, P <0.05 vs. non-AKI; *, P <0.05 vs. mild AKI.
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be interpreted with the existence of preoperative CKD.
This interpretation might be consistent with a report by
Endre and colleagues, who described the improvement
of new urinary AKI biomarkers, including NGAL, cysta-
tin C, KIM-1 and interleukin-18 by stratification with
baseline renal function [14]. Actually, ROC analysis in
this study revealed that the cutoff values of plasma
NGAL for AKI defined by the Youden index in the non-
CKD patients were all below 150 ng/ml, whereas results
obtained with the CKD patients showed cutoff values
that were mostly greater than 150 ng/ml. It is quite pos-
sible that the performance of plasma NGAL would be
reduced without consideration of baseline renal function
and without application of a proper threshold value forAKI diagnosis. Haase-Fielitz and colleagues measured
serum NGAL in an adult cardiac surgery cohort at a
single center (n = 100; CKD 27%). They observed no
preoperative difference of serum creatinine or serum
NGAL between AKI and non-AKI patients [16]. Further
investigation with a larger sample size in a multicenter
study is necessary to ascertain the impact of pre-existing
CKD on plasma and serum NGAL levels before introdu-
cing NGAL measurement to clinical use.
Although preoperative plasma NGAL was useful to
identify the high-risk patients for AKI after the surgery
(Table 2), increased NGAL from preoperative values will
not enable us to detect AKI early after the surgery
because of its transient decrease at 0 to 4 h, especially in
the CKD patients. However, the patients of CKD(+) AKI



















(n = 44) (n = 9) (95% CI) (ng/ml) (ng/ml) (ng/ml)
pre 122.5 (71.3 to 241.5) 482.0 (178.4 to 531.0)# 0.77 472 67% 89% 75 30% 785 11%
(0.55 to 0.90)
0 h 125.0 (90.0 to 187.8) 162.0 (121.0 to 272.0) 0.66 254 44% 89% 61 5% 469 0%
(0.44 to 0.83)
2 h 143.0 (89.7 to 238.8) 268.0 (171.0 to 419.0)# 0.75 170 89% 61% 89 23% 861 0%
(0.54 to 0.88)
4 h 152.0 (92.9 to 228.8) 383.0 (235.0 to 619.5)# 0.81 220 89% 75% 100 27% 608 28%
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Figure 4 Plasma NGAL values in de novo AKI and AKI superimposed o
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Figure 3 Peak time of plasma NGAL and serum creatinine. (A)
Time points of the highest plasma neutrophil gelatinase-associated lipocalin
(NGAL) and serum creatinine values in mild acute kidney injury (AKI) patients
(n = 39). (B) Time lags of the peaks between plasma NGAL and serum
creatinine in each AKI patient. Negative values indicate plasma NGAL started
to decrease earlier than serum creatinine did. Serum creatinine started to
decrease earlier than plasma NGAL in only 8 of 39 mild AKI patients (21%).
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creased before the surgery (>300 ng/ml) showed further
elevation of plasma NGAL 12 h after the surgery and
thereafter (Additional file 2: Figure S2B). In addition,
the highest value of postoperative plasma NGAL was
observed earlier than that of serum creatinine not only
in mild AKI (Figure 3) but in these CKD(+)AKI(+) pa-
tients (Additional file 2: Figure S2C, D). These observa-
tions suggest that plasma NGAL is useful not for early
AKI detection but for predicting the severity of AKI
earlier than serum creatinine. We calculated the ad-
justed blood creatinine and NGAL levels at 0 h by con-
sidering the impact of fluid accumulation during
surgery (Additional file 3: Figure S3). Even after adjust-
ment for fluid accumulation, transient decreases of
plasma NGAL but not serum creatinine at 0 to 4 h after
the surgery was observed in the CKD(+)AKI(+) group.
This result indicates another unknown mechanism that
causes transient suppression of plasma NGAL in CKD
induced by cardiac surgery rather than dilution. Further
evaluation is necessary to confirm these observations.
Cai and colleagues reported that several different
molecular forms of NGAL were found in human urine
and that the monometric form is predominantly secreted
by cultured renal tubular epithelial cells, whereas the
dimeric form is predominantly secreted by neutrophils
[35]. NGAL was first characterized as a protein com-
plexed with metallopeptidase 9 (MMP-9) released from
stimulated neutrophil [36]. Therefore, it is important to
clarify the measured forms of NGAL by the assay. This
study used sandwich format immunoassay. The anti-
bodies that were used recognize only the free form of*
12 h 24 h 36 h 60 h





n CKD. Values of plasma neutrophil gelatinase-associated lipocalin
)AKI(−) (n = 39), and CKD(+)AKI(+) (n = 33)). #, P <0.05 vs. CKD(−)AKI(−);
ease.















(n = 78) (95% CI) (ng/ml) (ng/ml) (ng/ml)
pre 0.69 73 65% 75% 52 33% 298 15%
(0.55 to 0.81)
0 h 0.76 102 65% 90% 49 33% 147 23%
(0.60 to 0.87)
2 h 0.67 142 45% 90% 48 19% 220 13%
(0.50 to 0.80)
4 h 0.76 72 90% 60% 49 28% 226 15%
(0.60 to 0.86)
12 h 0.73 90 70% 76% 48 26% 226 15%
(0.56 to 0.85)
24 h 0.73 91 75% 66% 47 14% 240 20%
(0.57 to 0.84)
36 h 0.63 113 55% 72% 44 10% 376 5%
(0.46 to 0.77)
















(n = 68) (95% CI) (ng/ml) (ng/ml) (ng/ml)
pre 0.71 472 33% 100% 68 23% 341 33%
(0.56 to 0.82)
0 h 0.75 111 76% 63% 77 32% 233 30%
(0.61 to 0.85)
2 h 0.75 233 52% 94% 59 16% 241 44%
(0.61 to 0.85)
4 h 0.74 163 70% 69% 69 16% 286 40%
(0.60 to 0.84)
12 h 0.72 340 42% 97% 71 19% 322 42%
(0.58 to 0.83)
24 h 0.77 241 59% 85% 70 24% 363 43%
(0.63 to 0.87)
36 h 0.71 373 45% 94% 71 11% 379 44%
(0.56 to 0.82)
60 h 0.66 537 31% 97% 62 10% 432 31%
(0.51 to 0.78)
AUC-ROC, area under the curve operating characteristic curves; CI, confidence interval; CKD, chronic kidney disease; NGAL, neutrophil gelatinase-associated lipocalin.
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dimeric complexes with MMP-9 [26].
Several limitations possibly affected the results ob-
tained in this study. First, although the patients were
enrolled at two general hospitals, their number (n = 146)
might be insufficient to determine the reliability and
generalizability of plasma NGAL. Recently, a large multi-center cohort study (TRIBE-AKI) of 1,219 adult patients
undergoing cardiac surgery evaluating urinary IL-18,
urinary NGAL, or plasma NGAL was reported [37].
Thirty-five percent of this cohort had CKD (eGFR <60).
The discriminatory ability of plasma NGAL did not
differ by CKD. It is noteworthy that only 60 patients
developed AKI, as defined differently from the present
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atinine after surgery). Second, AKI was diagnosed only
with serum creatinine. Although the AKIN criteria sug-
gest the use of another criterion based on urine output,
recent studies have frequently employed the serum
creatinine-based criterion alone [38]. Finally, AKI diagno-
sis based on serum creatinine might underestimate renal
injury. It has been suggested that a composite endpoint by
clinical events other than a short-term change in serum
creatinine should be regarded as a major adverse kidney
event. A multicenter pooled analysis of NGAL in AKI re-
vealed that the subgroup of increased NGAL with no
serum creatinine elevation (NGAL-positive creatinine-
negative) had adverse clinical outcomes including mortal-
ity, dialysis requirement, ICU stay and overall hospital stay
[39]. Recently, the 10th Consensus Conference of the
Acute Dialysis Quality Initiative (ADQI) reported a com-
bination of kidney functional (serum creatinine and urine
volume) and damage markers (new biomarkers including
NGAL) to stratify patients with AKI [40]. AKI can be di-
agnosed only using damage markers, such as NGAL, even
when no change in serum creatinine or urine volume is
observed (structural AKI). Pickering and colleagues evalu-
ated the performance of plasma NGAL on structural AKI
defined by increased urine NGAL with an adult ICU
cohort [41], although this study did not evaluate the
performance of plasma NGAL on creatinine-independent
diagnosis of AKI occurred in a different cohort of post-
cardiac surgery. Additional evaluation must be undertaken
to clarify the role of plasma NGAL for detecting structural
AKI that would be diagnosed independently from serum
creatinine values.
Conclusions
This study demonstrated that preoperative plasma
NGAL measurement is useful for identifying a high-risk
population of AKI. Although a transient decrease of
plasma NGAL occurred immediately after surgery (0 to
4 h), especially in AKI superimposed on CKD, plasma
NGAL showed an earlier peak than did serum creatin-
ine, indicating that plasma NGAL can predict the recov-
ery of AKI earlier. Moreover, determining different
cutoff values of postoperative plasma NGAL for de novo
AKI and AKI superimposed on CKD was necessary
for accurate AKI diagnosis. Further investigation is
necessary to confirm these findings because this study
enrolled a small number of patients.
Key messages
 This study evaluates plasma NGAL in AKI
occurring in patients with and without CKD after
cardiac surgery because CKD is a strong risk factor
for AKI development. Preoperative plasma NGAL, estimated GFR and
operation time are independently and significantly
associated with AKI occurrence after surgery.
 Although AKI superimposed on CKD showed the
highest plasma NGAL levels after surgery, plasma
NGAL alone was insufficient to discriminate de novo
AKI from CKD without AKI after surgery.
 Plasma NGAL showed an earlier peak than serum
creatinine did, indicating that plasma NGAL can
predict the recovery of AKI earlier.
Additional files
Additional file 1: Figure S1. The following additional data are available
with the online version of this paper. ROC analysis for AKI diagnosis at
each time point. Among 143 enrolled patients, 68 patients were
diagnosed as having CKD and 78 were not (non-CKD). ROC curves for AKI
diagnosis in non-CKD (A-H) and CKD (I-P) are shown. Three cutoff values
determined by Youden index, 95% sensitivity and 95% specificity are illus-
trated on the curve. The AUC-ROC values are presented in Table 3.
Additional file 2: Figure S2. The following additional data are available
with the online version of this paper. Time course of plasma NGAL and
serum creatinine in AKI superimposed on CKD. The CKD(+)AKI(+)
group was divided into two groups by preoperative plasma NGAL values
(Pre NGAL <300 ng/ml (n = 22) and Pre NGAL >300 ng/ml (n = 11)).
Values of serum creatinine (A) and plasma NGAL (B) in each group are
shown. (C) Time points of the highest plasma NGAL and serum creatinine
values in the Pre NGAL >300 ng/ml group (n = 11). (D) Time lags of the
peaks between plasma NGAL and serum creatinine in each AKI patient.
Negative values indicate plasma NGAL started to decrease earlier than
serum creatinine. #, P <0.05 vs. before surgery (pre).
Additional file 3: Figure S3. The following additional data are available
with the online version of this paper. Dilution effect on serum creatinine
and plasma NGAL at 0 h. Values of serum creatinine (A) and plasma NGAL
(B) before surgery and at 0 h (with and without adjustment by fluid
accumulation) are shown (CKD(−)AKI(−) (n = 54), CKD(−)AKI(+) (n = 20), CKD
(+)AKI(−) (n = 39), and CKD(+)AKI(+) (n = 33)). #, P <0.05 vs. before surgery
(pre), *, P <0.05 vs. 0 h.
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